ATC Group: N06AA21 Maprotiline

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06AA21 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06A Antidepressants
4 N06AA Non-selective monoamine reuptake inhibitors
5 N06AA21 Maprotiline

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.1 g
PAREN - Parenteral 0.1 g

Active ingredients in N06AA21

Active Ingredient Description
Maprotiline

Maprotiline is a tetracyclic antidepressant, psychoanaleptics, non-selective mono-amine reuptake inhibitor, which shares a number of basic therapeutic properties with the tricyclic antidepressants. It displays a well-balanced spectrum of action, brightening mood and alleviating anxiety, agitation and psychomotor retardation. In masked depression, it can exert a favourable influence on somatic symptoms.

Related product monographs

Title Information Source Document Type  
LUDIOMIL Film coated tablet Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Cyprus (CY)

France (FR)

Israel (IL)

Japan (JP)

Poland (PL)

South Africa (ZA)

Spain (ES)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.